NCT05568706Phase 2Completed

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

Study sponsor: Enanta Pharmaceuticals, Inc · ENTA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-06-23Actual
Enrollment · participants187Actual
Source updated2026-08-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Time to resolution of RSV Lower Respiratory Tract Disease (LRTD) symptoms. After: Measure: Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms Measure: Time to Complete Resolution of LRTD Symptoms for the mITT Population Measure: Time to Complete Resolution of LRTD Symptoms for the HR3 Population.

Actual enrollment increased by 1 participants

Before: 186 participants (actual). After: 187 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview